program 14th national conference 2nd annual meeting

RNAA NMD R M S
G
FO
R O IO
P G I S T R ATD AT I O N
RE
MO
OM
ACC OSED
L
ESE
ENC
AND OR TH
N
TIO
N F
BLE
T R A D AT I O
S
ILA
I
A
G
V
E
O
R
M
RE A
OM
ACC INGS A
T
MEE NE
LI
ON
AUSTRALIA’S CITY OF CULTURE, INVITES YOU TO
THE AUSTRALASIAN COLLEGE OF DERMATOLOGISTS
48TH ANNUAL SCIENTIFIC MEETING
SATURDAY 16 MAY to TUESDAY 19 MAY 2015
’ AS
SES
TIO
N
NC
E
R
E
IA
SOC
E
F
N
O
MA
L CMAY 2015
A
DER
TS
N
N
IA
17
GIS
L
O
O
Y
A
L
I
A
TR
AT O
A TAND SUND
AUS
N
ERM
D
H
Y
TIC
SME
O
1 4URTDAY 16 MA
G
C
N
OF
I
Y
T
T
T
A
E
E
I
S
E AY 2015
SOC
M
AN
I
L
S
A
A SDAY 19 M
U
RAL
T
S
N
E
AU
D TU
AN
N
A
D
2 N 18 MAY
OG
TOL
MON
UR
Y N
DAY
A D EL AI D E C ON VEN TI ON C EN T R E , A D E L A ID E , SO UT H AUST R A LIA , AUST R A LIA
THE
OFDERMATOLOGISTS
DERMATOLOGISTS
THEAUSTRALASIAN
AUSTRALASIAN COLLEGE
COLLEGE OF
The 48th Annual Scientific Meeting of the Australasian College of
Dermatologists will be held at the Adelaide Convention Centre (ACC),
Adelaide, South Australia, from Saturday 16 May to Tuesday 19 May 2015.
48TH
ANNUAL
SCIENTIFIC
MEETING
48th
ANNUAL
SCIENTIFIC
MEETING
2015
This brochure sets out the program and other information for the 48th
Annual Scientific Meeting of the Australasian College of Dermatologists
which will be held in Adelaide.
The convenors of the meeting are Dr Karen Koh, Dr Priya Selva-Nayagam
and Dr Sachin Vaidya. The South Australian Faculty welcomes Fellows,
trainees, students and other medical practitioners to the meeting.
It also includes the programs for the meetings of the Australian
Dermatology Nurses’ Association and the Australasian Society of Cosmetic
Dermatologists. You can register for any or all of the three meetings on
the single registration form which accompanies this brochure. Online
registration if eligible, for all three meetings is also available through the
College website: www.dermcoll.edu.au.
The Annual Scientific Meeting program incorporates major changes to the
meeting previously adopted by the College. These include that the meeting
is now four days duration, commencing on Saturday and finishing on
Tuesday; that there will be concurrent sessions including incorporating the
Australasian Society of Cosmetic Dermatologists and overlapping with both
the Australian Dermatology Nurses Associations’ meeting and the meeting of
the Australasian Society for Dermatologic Research. This will offer delegates
a variety of choices.
I am pleased that the meeting will be strongly supported by the pharmaceutical
and allied health industries, both as sponsors and as trade exhibitors.
Full details of all aspects of the meeting will be announced in the final
program available both upon arrival at the meeting and prior, on our
website, www.dermcoll.edu.au.
I hope you will join us in what promises to be one of our most exciting
meetings. I look forward to catching up with you in Adelaide.
A/Prof. Stephen Shumack, OAM, FACD, FAICD
2
Adelaide has been voted Australia’s most liveable city and one of Lonely Planet’s top 10 must-visit cities for
2014. It is undoubtedly the cultural capital of Australia. With its elegant, historic buildings, its wide boulevards,
its easily manageable grid street pattern, its Victorian-era parks and monuments, Adelaide is the jewel in the
Australian crown.
The city is characterised by elegant shopping arcades, wine bars and coffee shops, some 700 restaurants,
pubs, cafes and eat streets and many art galleries and museums.
South Australia itself is home to stunning beaches and award-winning wine events and festivals. Adelaide
is the gateway to the Barossa, the Adelaide Hills, Flinders Ranges, the outback and Kangaroo Island. The
South Australian coastline is more than 3,800 km long and is punctuated by towns, beaches, cliffs and jetties.
Many coastal regions offer fantastic fishing, boating and surfing, as well as quality wines and fresh produce,
including local seafood.
North Terrace is Adelaide’s cultural boulevard, with its many art and cultural sites, including the Art Gallery of
South Australia, the Migration Museum and the South Australian Museum. It is also the site of the re-developed
Adelaide Convention Centre, the venue for the Annual Scientific Meeting. Immediately adjoining, are the new
South Australian Health and Medical Research Institute (SAHMRI) and the re-located Royal Adelaide Hospital.
For more information, please visit www.southaustralia.com/regions/adelaide-city-visitor-information-centres.aspx.
3
Adelaide Convention Centre
North Terrace
ADELAIDE SA 5000
Australia
T +61 8 8212 4099
F +61 8 8212 5101
Whttp://www.adelaidecc.com.au/
The ACC has undergone a major re-development and extensions. Adelaide now has the newest and most
modern convention facilities in Australasia. The ACC now occupies a much greater part of North Terrace,
stretching from the Adelaide Festival Centre to Morphett Street. Access from Morphett Street is now the
principal entry point for the venue.
The new ACC extensions include plenary halls, meeting rooms and a ballroom. These will form the venue for
the College meeting.
The plenary sessions will be held in the Hall L. Concurrent sessions will be held in Hall M. The Registration
Desk will be located in the Hall M Foyer. The Conference organiser’s office and secretariat will be in the Hall
H Office. The trade exhibition will be in Hall H.
Morning and afternoon teas and lunches will be served in the trade exhibition.
4
UPPER LEVEL
WEST
CENTRAL
EAST
FOYER A
FOYER B
STAIR
PANORAMA
BALLROOM
PANORAMA
FOYER
A
SKYWAY
LIFT
P1 P2
B
LIFT
P3
ESCALATOR
STAIR &
ESCALATOR
PANORAMA
ROOMS
SKYWAY
FOYER
S1
LIFT
ESCALATOR
S2
S3
CITY
SUITE
FOYER
CS1
CS2
PROPOSED
STAGE 2
DEVELOPMENT
SKYWAY
ROOMS
STAIR
CITY
SUITES
CS3
CS4
CITY
ROOMS
CITY
FOYER
1
C1 C2 C3 C4
CITY
FOYER
2
CITY
CITY
FOYER FOYER 4
3
CITY
TERRACE
GROUND LEVEL
WEST
CENTRAL
EAST
FESTIVAL DRIVE
RIVERBANK
CAR PARK
PANORAMA
SUITE
LIFT
FOYER E
STAIR
STAIR
FOYER F
FOYER
L2
FOYER
L3
LIFT
OFFICE F
MONTEFIORE ROAD
L1a
WESTERN
ENTRANCE
STAIR
L1b L2
L3
F
STAIR &
ESCALATOR
G
C
RECEPTION
FOYER G
LINK
OFFICE
H
H
N
FOYER H
O
MAIN
ENTRANCE
OFFICE K
I
NORTH
TERRACE
CAR PARK
J
K
PLAZA
ACCESS
RAMP
LIFT
LOADING
DOCK
D
PROPOSED
STAGE 2
DEVELOPMENT
ATRIUM
ENTRANCE
M
LIFT
E3
ATRIUM
FOYER
LIFT
STAIR
E2
ESCALATOR
L
FOYER M
E1
LIFT
LIFT
FOYER L
ESCALATOR
RIVERBANK
CAR PARK
STAIR
HOTEL INTERCONTINENTAL
FOYER
L1
ATRIUM
ENTRANCE
ESCALATOR
NORTH TERRACE
LOWER LEVEL
WEST
CENTRAL
RIVERBANK
OFFICE
FOYER
R4
STAIR
FOYER
R8
FOYER
R7
R8
R8b
FOYER
R5
FOYER
R6
LIFT
R4
R7
R6b
RIVERBANK
BOARD ROOM
FOYER FOYER
R3
R2
R3
R2
R6
R1
FOYER
R1
STAIR
R5
REGATTAS
BISTRO
LIFT
RIVERBANK
ROOMS
27/02/2014
5
The visiting speakers will be:
Marcus Maurer, MD
Marcus Maurer is Professor of
Dermatology and Allergy and
Director of Research at the
Department of Dermatology and
Allergy, Allergie-Centrum-Charité
of the Charité - Universitätsmedizin
in Berlin. He is also Head of the
Specialty Clinics for Urticaria, Mastocytosis, Pruritus,
Autoinflammatory Disorders and Angioedema and the
Dermatological Allergology Laboratory. His areas of
interest include the characterisation of physiological
functions of mast cells, neuroimmunology, inflammation,
innate immunity, tolerance and pathogenesis and
treatment of urticaria, mastocytosis, hereditary
angioedema (HAE) and autoinflammatory diseases.
Professor Maurer has authored more than 290
publications in peer-reviewed journals. He currently serves
as a member of the following Editorial Boards: Advances
in Dermatology and Allergology, International Archives
of Allergy and Immunology, Allergo Journal, Allergy,
Experimental Dermatology and the WAO Journal.
Professor Maurer’s participation in the meeting is
assisted by an unconditional grant to College by
Albert C. Yan, MD
Dr Yan currently serves as the Chief of
the Section of Paediatric Dermatology
at the Children’s Hospital of
Philadelphia where he is Professor
of Paediatrics and Dermatology at
the Perelman School of Medicine at
the University of Pennsylvania. He
received his AB in Philosophy from Princeton University
and his MD from the University of Pennsylvania.
He is a past President of the Society for Paediatric
Dermatology, and is the incoming Chair of the AAP
Section on Dermatology Executive Committee. Dr Yan
is also the co-chief Editor of the 3rd edition of Harper’s
Textbook of Paediatric Dermatology. His areas of interest
include acne, atopic dermatitis, haemangiomas and
vascular anomalies, skin infections as well as paediatric
dermatology education and workforce issues.
Christoph Martschin, MD
Dr Martschin is a senior consultant
dermatologist in medical and
aesthetic dermatology in Sweden. He
was educated at Innsbruck Medical
University, Austria and undertook
training in aesthetic dermatology in
the USA, UK, Germany and Sweden.
In 2012-13 he worked at Karolinska University Hospital
in Stockholm before entering private practice. He lectures
and trains in injection technique with focus on facial
volume restoration, lip augmentation, skin boosters,
facial anatomy and prevention/treatment of side-effects.
He serves on advisory boards for Botulinum toxin and
injection strategy.
Amit G. Pandya, MD
Dr Pandya is a Professor in the
Department of Dermatology at the
University of Texas Southwestern
Medical Center in Dallas, Texas, USA.
He earned his Doctor of Medicine
degree from UT Southwestern
Medical School and completed
residencies in internal medicine at Presbyterian Hospital
of Dallas and in dermatology at UT Southwestern
Medical Center. Dr Pandya has a special interest in
vitiligo, melasma and other pigmentary disorders. His
ongoing clinical research is focused on the etiology,
epidemiology, measurement, quality of life, diagnosis
and treatment of these cutaneous disorders.
J ohn G. Albertini, MD
Dr Albertini currently serves as
President of the American College
of Mohs Surgery (ACMS), founded
in 1967 by Dr Frederic Mohs for
fellowship-trained skin cancer and
reconstructive surgeons. He attended
medical school at The University
of Chicago. He then trained at UC San Francisco in
Internal Medicine (internship) and Geisinger Medical
Center in Dermatology and Mohs Surgery (residency and
fellowship). After active duty Air Force military service in
San Antonio, Texas as Chief of Mohs Surgery, he entered
private practice at The Skin Surgery Center in North
Carolina where he has been recognised annually as
a ‘Best Doctor’ since 2005. He has presented over 50
local, regional and national lectures and has published
over 40 scientific articles and book chapters. Dr
Albertini has served as President of the North Carolina
Dermatologic Association (2009) and as Assistant Editor
of the Journal Dermatologic Surgery (2009-2015). He
was invited to be Guest Editor for the Special Issue on
Advanced Reconstruction published in 2014. Dr Albertini
also served as Fellowship Director of an ACMS and
ACGME approved training program in Mohs surgery
and procedural dermatology (2007-2013). He currently
collaborates with faculty and helps trains residents in his
role of Associate Professor (Volunteer) at Wake Forest
University Department of Plastic and Reconstructive
Surgery.
Torsten Walker, MD
Following his education at the
Universities of Graz, Heidelberg and
New York, Dr Walker specialised as
a dermatologist in Ludwigshafen and
Amberg in Germany. His doctorate
thesis was about penicillin allergy
and diagnostic problems. Following
board certification he specialised in aesthetic treatments.
From 2005 to 2012 he was senior physician in the
Department of Dermatology in Wiesbaden. He runs
his own private clinic in Ludwigshafen with an aesthetic
focus. He is experienced in Botulinum toxin A treatments,
fillers and liposuction and especially in deep chemical
peel with Phenol solution. Dr Walker is a member of the
German Botulinum Toxin Society, an honorary member
of the Jordanian Dermatologic Society and a founding
member of the International Peeling Society.
Dr Walker’s participation in the meeting is
assisted by an unconditional grant to College by
6
Sponsored speakers will participate in sponsored
symposia or breakfast sessions, and possibly also in the
main program. They include:
Dr Jeremy B. Green
Dr Green is a fellowship-trained,
board-certified, cosmetic dermatologist
who completed his medical education
at the Northwestern University
Feinberg School of Medicine and the
University of Miami Miller School of
Medicine where he graduated with
Alpha Omega Alpha (AOA) honours. He trained at the
University of Miami Department of Dermatology and
Cutaneous Surgery where he served as its chief resident.
Dr Green completed advanced fellowship training in laser
and cosmetic surgery at SkinCare Physicians in Boston,
Massachusetts with clinical faculty from the Harvard and
Yale Departments of Dermatology.
Dr Green has authored numerous peer-reviewed
publications and lectures, both nationally and
internationally on cosmetic dermatology and laser
surgery. He has presented at the annual meetings of the
American Academy of Dermatology, the American Society
for Laser Medicine and Surgery and the American Society
for Dermatologic Surgery, among others. Dr Green is also
a Voluntary Assistant Professor at the University of Miami
Department of Dermatology where he provides patient
care at Jackson Memorial Hospital and participates in
resident education.
Dr Green’s participation is made possible by the generous
support of
Professor Thomas Luger
Professor Luger is director and
chairman of the Department of
Dermatology at the Westfalische
Wilhelms-Universitat in Munster,
Germany and head of the Ludwig
Boltzmann Institute for Cell Biology
and Immunology at the University.
He has been Dean of the University’s Medical Faculty;
and General Secretary and then President of the German
Dermatological Society. His special field of interest is atopic
dermatitis.
Professor Luger’s participation is
made possible by the generous support of
Dr Emil Tanghetti
Dr Tanghetti was born and raised
in Sacramento. He attended the
University of California Davis where
he excelled in his studies and received
early admission to USCLA School
of Medicine after only three years
of undergraduate studies. Upon
completing his medical studies and a one year pathology
fellowship. Dr Tanghetti graduated first in his class and
received the Dean Warren Medal for Academic Excellence.
After finishing residencies in internal medicine at Stanford
University and dermatology at Harvard School of Medicine,
he completed a photo-medicine fellowship at the Wellman
Laboratories at the Massachusetts General Hospital.
Dr Tanghetti is a board-certified dermatologist and a
Fellow of the American Academy of Dermatology and
the American Society for Laser Medicine and Surgery. He
is currently listed in the “Best Doctors in America Pacific
Region” and recognised as “Top Doc” by his peers in
Sacramento Magazine. Dr Tanghetti has received the “Hero
in Health Care” award for his volunteer work in removing
tattoos for the California Youth Authority. Dr Tanghetti has
been active in clinical studies for over a decade.
Dr Tanghetti’s participation is made
possible by the generous support of
Professor Eggert Stockfeth
Professor Stockfleth is Director of the
Skin Cancer Center Charité, Berlin. He
gained his medical degree in 1991
from the University of Hamburg and
since then has held positions at a
number of universities and institutions
both in Germany (amongst others at
the German Cancer Research Center, Heidelberg) and the
USA. He joined the University of Kiel in 1996 and in 1999
he was made Consultant of Dermatology, Venereology
and Allergology. In 2001 he became University Professor
at Charité – University Medical Center Berlin. Since 2004
he is the Head of the Skin Cancer Center Charité and
since 2009 he is the Vice-Chairman of the Department of
Dermatology, Venereology and Allergy.
He is a member of a number of professional associations
including the Berlin Society of Dermatology, the German
Society of Dermatology, the Hamburg Dermatology
Association, the German Cancer Association, the German
Dermatology Association, the European Academy
of Dermatology and Venereology and the European
Dermatology Forum. He is also the former European
President of Skin Care in Organ Transplant Patients
Network (SCOPE). In 2008 he was one of the founders of
the European Skin Cancer Foundation, which aims to assist
in developing and providing standardised treatments on a
European level.
His research on dermatology, oncology and particularly
skin cancer, has been extensively published in peerreviewed journals. He acts as referee for many different
journals including Journal of Infectious Diseases,
International Journal of Cancer, Journal of Investigative
Dermatology and The Lancet. His interests include:
oncology, HPV-associated skin and mucosal skin tumours,
skin tumours in organ transplant patients, general
dermatology, apoptosis regulation, skin carcinogenesis,
Immunology, tumorimmunology, molecular biology of skin
tumours (melanoma, cutaneous lymphoma, cutaneous
squamous cell carcinoma).
Dr Stockfleth’s participation in the meeting
is made possible by the generous support of
7
The following special events will be held in association with the meeting:
University of South Australia, City West Campus, Lecture Theatre HH3-09, Adelaide
Friday 15 May 2015
For more information, visit https://www.skincancer.asn.au/events/12/2015-patch-test-training-day.
If you have any enquiries, please contact Amanda Palmer telephone: 03 9623 942 or email apalmer@
occderm.asn.au or A/Prof. Rosemary Nixon email: rnixon@occderm.asn.au.
Stamford Plaza Adelaide Hotel
Friday 15 May and Saturday 16 May 2015
Convenors: A/Prof. Nikolas Hass and A/Prof. Helmut Schaider.
For more information visit the website www.asdr.org.au/2015-asdr-conference.
Adelaide Convention Centre
Saturday 16 May and Sunday 17 May 2015
For more details contact Australian Dermatology Nurses’ Association Secretary, Lynne Anderson, email:
secretary@adna.org.au
Adelaide Convention Centre
Monday 18 May and Tuesday 19 May 2015
For more information, contact A/Prof G Goodman
email: gg@div.net.au.
8
The Registration Desk will be located in the Hall M Foyer. The
conference organiser’s office and the College secretariat will be
in the Hall H Office. The registration desk will open on Saturday
16 May from 0800 and throughout the meeting. The College
secretariat office will be open from 1000 to1600 daily.
For the first time, College will have its own stand in the trade
exhibition, manned by members of the College staff.
Come and meet us and find out what we can do for you. Pick up
some leaflets and other freebies; find out about the website; check
your CPD.
We are located just to the left, inside the main entrance of the trade
exhibition.
The trade exhibition will be in Hall H. It will be open on the
following days:
Sunday 17 May from 1000 to 1600 (1245 official opening)
Monday 18 May from 1000 to 1600
Tuesday 19 May from 1000 to 1500
The morning and afternoon tea breaks will be for half an hour. The
lunch break will normally be one hour, except on Monday 18 May
and Tuesday 19 May 2015 when it will be longer.
College is offering a free downloadable web-based app for the
Annual Scientific Meeting. It will include information about the
scientific program, social program, accommodation, etc. It will also
be used for responder sessions during the meeting. The app can be
used on most iPhones, notebooks and laptops.
9
The plenary sessions of the meeting will be held in Hall L. The concurrent sessions will be held in Hall M.
Please indicate on the registration form which sessions you intend to attend. For dermatologists and trainees of
College, if attending Saturday 16 May only, a one day registration fee will be available.
T H E A U S T R A L A S I A N C O L L E G E O F D E R M AT O L O G I S T S 4 8 T H A N N U A L S C I E N T I F I C M E E T I N G
Saturday 16 May 2015
1400-1530CONCURRENT
SYMPOSIUM
1A: PSORIASIS
SYMPOSIUM
Chair: Dr S. Sidhu
A/Prof. P. FoleyUpdate on
biologics including
biosimilars
Dr R. StapletonThe value of
QFN gold in
pre-screening
assessments for
non-biologic
immunosuppressive
agents
Dr E. PontifexPsoriatic
arthropathy
assessment for the
dermatologist
Panel discussionPresentation of
challenging case
studies
CONCURRENT SESSION 1
CONCURRENT SESSION 1
0730-0830MENARINI SPONSORED
BREAKFAST: A MASTERCLASS
WITH PROF. EGGERT STOCKFLETH:
EVIDENCE-BASED MANAGEMENT
OF FIELD CANCERISATION
Speaker: Prof. Eggert Stockfleth
0845-1300
REGISTRARS’ TRAINING SESSION
A/Prof. G. Fischer/ Education update
Dr D. Stanford/
Dr A. Lim
A/Prof. S. Zagarella/Evidence-based medicine – basic
Dr K. Chen
principles
Dr A. SheridanMohs surgery – what registrars need
to know
Dr M. Gupta/
Methotrexate and psoriasis
Dr M. Andrews
Dr L. Warren
When things REALLY go wrong
Dr R. Waddell
Syphilis in 2015
1400-1530CONCURRENT SYMPOSIUM 1B:
REGISTRARS’ FORUM
Chair: Dr K. Koh
Dr M. CicchielloAssessment of delays to diagnosis of nodular
melanoma compared to superficial spreading
melanoma
Dr A. InghamMultiple Orf lesions in an immunocompetent
patient treated successfully with imiquimod
Dr M. AbikhairThe off-label use of infliximab in
dermatology: A review of 22 cases
Dr L. ByromTelederm National: A decade of
teledermatology
Dr C. KalaiKimura’s disease arising from prurigo
nodularis
Dr B. KimScar outcomes in dermatologic surgery
Dr P. SobarunLocalised IgG4-related skin disease, a rare
clinical entitiy
Dr C. Wong
Think UV, not heat!
Dr P. ChenIllness perception in association with
psychological functioning in patients with
discoid lupus erythematosus
Dr B. SwanPulsed dye laser treatment at 2 weekly
compared to 3 monthly intervals in infants
with capillary malformations
Dr R. SaundersonPerianal ulceration misdiagnosed as
pyoderma gangrenosum
Questions
1600-1730LA ROCHE-POSAY SPONSORED SYMPOSIUM: TARGETING THE HUMAN SKIN MICROBIOME
IN PATIENTS WITH ATOPIC DERMATITIS
Speaker: Prof. T. Luger
In patients with atopic dermatitis, a marked change in the skin micrbiome diversity has been
shown as a function of the disease severity. Exploration of the skin microbiome enables entirely
new approaches for the treatment of infectious and inflammatory skin diseases.
10
AU S TRA L I A N D E RM ATO LO GY N U RS E S ’
A S S O C I ATI O N 1 4 TH A N N UA L N ATI O N A L
C O N F E RE N CE
The scientific sessions of the meeting the will be held
in Hall K.
Saturday 16 May 2015
1000-1700MOHS’ PEER REVIEW SESSION
AND BUSINESS MEETING
Convenor: Dr T. Wiadrowski
1000-1530Mohs’ Peer Review Session
Introduction
Defect Reconstruction: Masters Panel:
A/Prof. J. Albertini, A/Prof. S. Huilgol,
A/Prof. C. Vinciullo
Up Top to Down Under: Forehead to
Nose, and other 2 Stage Flaps
Perioperative Issues:
Panel: A
/Prof. J. Albertini,
Dr M. Warner
QAP: Dr E. Yiasemides
General
1530-1630Mohs’ Group Business Meeting
1630
Mohs’ Meeting Cocktail Party
All Fellows are welcome to attend the Mohs’ Meeting
0800-
Registration open
0900-1000Keynote Speaker: RN S. Lawton,
OBE
My dermatology journey from RN
to OBE
1000-1030Dr B. De’Ambrosis
PNI and other nasties
1030-1100
Morning tea and networking
1100–1130Dr K. Newland
Cutaneous Lymphoma
1130-1200
Dr Y-C. Lee
TBC – possibly anti-wrinkle
injections and/or hyperhidrosis
1200–1230State Education Day
brainstorming
1230–1330
Lunch and networking
1330–1400P. Faga, RN
Anaphylaxis
1400-1430
Annual General Meeting
1430-1500
Afternoon tea and networking
1500-1530Dr P. Artemi
Surgical treatment of vitiligo
1530-1600Dr T. Artemi
Pharmacology in dermatology
1600-1630Dr E. Ryan
Talk on dermatology conditions
common to the outback
Proposed
CPD points: 5.5 hours
Social Program
Ego Nurses’ Dinner
National Wine Centre, Corner
Botanic Road and Hackney Road,
Adelaide
(ADNA members only, numbers
limited)
11
T H E A U S T R A L A S I A N C O L L E G E O F D E R M AT O L O G I S T S 4 8 T H A N N U A L S C I E N T I F I C M E E T I N G
0730-0830NOVARTIS SPONSORED
BREAKFAST: A NEW ERA
FOR PSORIASIS PATIENTS:
IL-17 INHIBITION
A/Prof. P. Foley
Welcome and introduction
Dr L. Spelman
IL-17 inhibition – the
evidence
Dr J. Sullivan
IL-17 inhibition – the patient
Q&A Panel Discussion
12
1115-1245CONCURRENT
SESSION 2A:
MELANOMA
SYMPOSIUM
Chair: Dr C. Reid
Dr G. CarlosReflectance
confocal
microscopy as
a diagnostic aid
in determined
invasion in lentigo
maligna clinical
presentations
Dr D. DeshpandeTopical and
intralesional
therapies for locoregional metastasis
of cutaneous
melanoma
A/Prof. N. HaassMaking stressed
melanoma selfdestruct
Dr K. CrottyBe aware of the
BAPoma
Dr M. BrownAdjuvant treatment
of melanoma
Questions
CONCURRENT SESSION 2
CONCURRENT SESSION 2
0845-0850OFFICIAL OPENING BY A/PROF.
S. SHUMACK, OAM, PRESIDENT,
AUSTRALASIAN COLLEGE OF
DERMATOLOGISTS
BREAKFAST SESSIONS
BREAKFAST SESSIONS
Sunday 17 May 2015
0730-0830JANSSEN SPONSORED
BREAKFAST: TREATING THE
FULL SPECTRUM: UNMET
NEEDS IN PSORIASIS
0850-1045
PLENARY SESSION 1
Chair: A/Prof. S. Shumack
Prof. M. MaurerProblems and solutions in the
management of chronic urticaria
Prof. A. PandyaMelasma: Differential diagnosis and
pathogenesis
Prof. A.YanPreadolescent acne: The argument
for early treatment
Prof. J. Albertini
Surgical pearls
Questions
1115-1245CONCURRENT SESSION 2B:
PAEDIATRIC DERMATOLOGY
SYMPOSIUM
Chair: Dr L. Warren
Dr C. BarnettAn update on genetic testing for the
dermatologist
Dr G. HarveyGenetics of a rare entity
Dr J. KernsBullous pemphigoid in infants –
characteristics, diagnosis and treatment
Dr C. ChaptiniPrevalence of methicillin-resistant
Staphylococcus aureus in children with
atopic dermatitis: A longitudinal study
Dr S. SmithAssessment of pharmacists’ knowledge
about use of topical corticosteroids
in atopic dermatitis: Pre and post
continuing professional development
education
Dr E. MooneyAdverse effects of topical corticosteroids
in paediatric eczema: Australian
consensus statement
Dr S. Strathie Page SCALP syndrome: A rare clinical entity
Dr C. ZhaoNeonatal autoimmune blistering
disease: A systematic review of the
literature
CONCURRENT SESSION 3
CONCURRENT SESSION 4
1545-1715CONCURRENT SESSION
4A: NON-MELANOMA
SKIN CANCER SYMPOSIUM
Chair: Dr W. Weightman
Dr R. CarrollImmune phenotype and
function: Management of
immunosuppression in high
risk SCC in renal transplant
recipients
Dr J. AlbertiniNon-melanoma skin cancer
– lessons I have learned
Dr M. ChoScalp basal cell carcinoma:
A review of 2202 cases
Dr A. GuptaManagement of squamous
cell and basal cell
carcinomas of the head and
neck with perineural invasion
Dr J. MaIn-transit squamous cell
carcinomas: An Australian
case series
Questions
CONCURRENT SESSION 4
CONCURRENT SESSION 3
1400-1500CONCURRENT SESSION
3B: CONTACT DERMATITIS
SYMPOSIUM
Chair: Dr L. Gordon
A/Prof. R. NixonOccupational hand
dermatitis in Victoria: Causes
and contributing factors
Dr C. HigginsOccupational contact
dermatitis among healthcare
workers: A retrospective
review
Dr A. LaljiThe European nickel
legislation – should Australia
follow?
Dr R. MeaniAn unusual reaction
following allergic contact to
grevillea Robyn Gordon
Dr P. TongAllergic contact dermatitis:
can your moisturizer be the
culprit?
Dr L. GordonAllergic contact dermatitis:
Yes, it was the clothes washing
Dr L. GordonMethylisothiazolinone – the
story continues…
1345-1515CONCURRENT SESSION 3B:
LASER SYMPOSIUM
Chair: Dr K. Koh
Dr D. LimHigh density 1927 thulium
laser for actinic keratoses – is
this the ideal field treatment?
Dr C. RobbA novel hybrid ablative
and non-ablative fractional
resurfacing treatment for
clinical efficacy with enhanced
patient experience
Dr M. RodriguesMedication-induced
pigmentation: A novel
treatment for an age-old
problem
Dr E. Tanghetti
Picosecond lasers
1545-1715CONCURRENT SESSION
4B: PIGMENTARY DISEASES
SYMPOSIUM
Chair: Dr S. Vaidya
Dr S. VaishampayanCommon and uncommon
dermatoses in darker skin
Dr M. RodriguesVitiligo: An approach to
treatment
Dr P. ArtemiNew surgical treatments for
vitiligo
Dr S. VaidyaApproach to
hypopigmentation or
depigmentation in children
Prof. A. PandyaManagement of
post inflammatory
hyperpigmentation
Dr A. LimLaser treatments in patients of
darker skin types
Questions
1830-1930GRADUATION ORATION AND
CONFERRING OF DIPLOMAS
AND AWARDS, ADELAIDE
CONVENTION CENTRE
John Reid Orator: Dr Peter
Goldsworthy, AM
Australian writer
and medical
practitioner
13
AUSTRALI AN DER M ATO LO GY N U R SE S’
ASSOCI AT I ON 1 4 TH A N N UA L N AT IO N A L
CONFE R ENC E
Sunday 17 May 2015
0730-
Registration open
0730–0830Janssen-Cilag Pharmaceuticals
Sponsored Breakfast: Biologics
CPD issued separately by JanssenCilag Pty Ltd
1000-1030A/Prof. P. Fernandez-Peñas
How light is used in dermatology
1030–1030S. Temby, RN
CPD requirements and how to
present for auditing
1030-1100
Morning tea in ACD Trade Exhibition
1100-1130
Dr S. Eisman
Pigmented lesions
1130–1200Dr L. Young
Topic: TBC
1200- 1300
Lunch in ACD Trade Exhibition
1300–1330G. Savoulian, RN
Treatment for chronic eczema from a
nurse’s perspective
1330-1400Dr A. Rudd
Topic: TBC
1400-1430Dr G. Marshman
Dermatologic challenges in West
Timor
1430-1445A. Palmer, RN
Contact Allergan Bank
1445-1500E. Senior, RN
Wound care case discussions
1500S. Temby, President, ADNA
Close of conference
1500-Afternoon tea in ACD Trade
Exhibition
Proposed
CPD points: 4.0 hours
14
T H E A U S T R A L A S I A N C O L L E G E O F D E R M AT O L O G I S T S 4 8 T H A N N U A L S C I E N T I F I C M E E T I N G
CONCURRENT SESSION 5
0845-1030
PLENARY SESSION 2
Chair: Dr J. Menz
Prof. M. MaurerChronic pruritus – what’s new in the
aetiology, diagnostic work up and
treatment?
Prof. A. Pandya
Management of melasma
Prof. M. MaurerInnate immunity and
autoinflammation – What do we
need to know as dermatologists?
Questions
1400-1500CONCURRENT
SESSION 5A: GENITAL
DERMATOLOGY
SYMPOSIUM
Chair: Dr P. Selva-Nayagam
A/Prof. G. FischerLong term management of
adult vulval lichen sclerosus:
A prospective cohort study of
507 women
Dr A. LeePre-pubertal onset vulval
lichen sclerosus: The
importance of maintenance
therapy in long-term
outcomes
Dr S. Strathie PagePlasma cell vulvitis:
Presentation of a case
Dr P.
Selva-NayagamPlasma cell vulvitis: Is it one
disease?
Dr S. BallOn your bike! – when cycling
is not always good for you
Dr D. VekicPhenotypic variations in
hidradenitis suppurativa
imply heterogeneous
pathogenic pathways
with potential adjuvant
therapeutic targets
BREAKFAST SESSIONS
0730-0830LILLY AUSTRALIA
SPONSORED BREAKFAST:
THE GREAT DEBATE:
GOALS OF TREATMENT
FOR SEVERE PSORIASIS –
DO WE NEED TO REDEFINE
THEM?
Chairs: A/Prof. P. Foley and
Dr W. Weightman
0730-0830LEO PHARMA SPONSORED
BREAKFAST: OPTIMISING
PATIENT OUTCOMES WITH
PICATO® GEL: HOW FAR
CAN IT GO?
Chair: Dr S. Smith
An interactive session on
improving patient satisfaction
within the clinic setting.
1100-1230
VIRTUAL CLINICAL MEETING
Chairs: Dr E. Ryan and Dr R.
Manifold
A variety of interesting clinical cases
will be presented for diagnosis and
discussion of management
CONCURRENT SESSION S
BREAKFAST SESSIONS
Monday 18 May 2015
1400-1500CONCURRENT SESSION 5A:
FREE PAPERS SESSION
Chair: Dr K. Newland
Dr A. ChongDermatology teaching in
Australian medical schools:
Preliminary survey results
Dr J. KernsMulticentric
reticulohistiocytosis:
Rituximab as an alternative to
established therapy regimens
Dr A. SahebianA review on dermatological
side effects of current
treatment regimens in lung
transplant recipients
Dr C. de BelilovskyEV.E.I.L.S PROGRAM: Ramanspectroscopic electron and
genomic characterization of
newborn and children skin
physiology
15
For Fellows and Associate
Members of College only.
16
CONCURRENT SESSIONS
CONCURRENT SESSIONS
1700-1800CYNOSURE
SPONSORED
SYMPOSIUM:
PICOSURE - PAST,
PRESENT AND
FUTURE
Speaker: Dr E.
Tanghetti
Questions
C O N C U RREN T S ES S IO N S
C O N C U RREN T S ES S IO N S
1530-1700ANNUAL GENERAL
MEETING
1530-1700REGISTRARS’ TEACHING
SESSION
For vocational trainees in
dermatology only.
Prof. A. PandyaUpdate on autoimmune
blistering conditions
Prof. A. YanApproaches to diagnosing
genetic skin disease
Prof. M. MaurerMastocytosis - present and
future treatment options
1700-1830CELGENE SPONSORED SYMPOSIUM:
UNDERSTANDING UNMET NEEDS
IN PSORIASIS, PSORIATIC ARTHRITIS
AND SMALL MOLECULE ORAL
TREATMENT OPTIONS
Chair: A/Prof. P. Foley
Speaker: A/Prof. P. Nash, Coast Joint
Care (QLD)
Session objectives:
- Understand unmet physician and
patient needs in psoriasis and
psoriatic arthritis
-U
nderstand the pathophysiology and
mechanisms of disease of psoriasis
and psoriatic arthritis
- Review the efficacy and safety for
small molecule oral therapies for
adults with moderate to severe plaque
psoriasis
- Identify distinctive features of psoriatic
arthritis and implications for clinical
management
1700
Arrival canapés and registration
1730A/Prof. P. Foley
Introduction and program objectives
1735A/Prof. P. Foley
Physician and patient unmet needs in
psoriasis and psoriatic arthritis
1740A/Prof. P. Nash
Intracellular cytokine signaling
pathways: A rational target in psoriasis
and psoriatic arthritis
1805A/Prof. P. Foley
Small molecule oral therapies for
psoriasis
1820A/Prof. P. Foley and A/Prof. P. Nash
Questions
A U S T R A L A S I A N S O C I E T Y O F C O S M E T I C D E R M AT O L O G I S T S 2 N D A N N U A L M E E T I N G
Monday 18 May 2015
BASIC PROGRAM
1000–1045SESSION 1: HOW TO START A
COSMETIC PRACTICE AND HOW
TO APPROACH A COSMETIC
PATIENT
Chairs: Dr B. Welsh and Dr N. Wines
Dr B. Welsh/
Stories from the front line –
Dr B.Pruimshowcasing practices
Dr J. GreenStarting injectables and cosmetic
pearls
Panel discussion
1045-1130SESSION 2: APPROACH TO THE
PATIENT: UNDERSTANDING AND
ASSESSMENT OF THE COSMETIC
PATIENT
Chairs: A/Prof. G. Goodman
and Dr N. Cook
Dr C. Martschin Personality profiles
A/Prof.
Patient assessment
G. Goodman
Questions and answers
1130–1200SESSION 3: ANATOMY OF
THE FACE AND NECK: FACIAL
ANATOMY FOR INJECTIONS
AND FIELD BLOCKS, LOCAL
ANAESTHESIA AND DANGER
AREAS
Chairs: Dr M. Freeman
and A/Prof. G. Goodman
Facial anatomy for injections
Field blocks, local anaesthesia and
danger areas
Dr C. MartschinAnatomy for fillers: Tips for avoiding
complications
PanelFavourite anaesthetic tricks/
techniques and concerns
1200-1300 SESSION 4: LASERS – HOW TO
INTRODUCE TO YOUR PRACTICE
Chairs: Dr R. Rosen and Dr S.
Manoharan
TBC
Laser introduction
Dr D. Lim/
What lasers / energy based
Dr A. Lim
technologies to start with?
Dr E. TanghettiVascular lasers - is there anything
new?
Tricks to enhance efficacy when
treating vascular lesions and two
wavelength devices 595/1064 –
when to use and why
1300-1400 LUNCH
1400–1430SESSION 5: LASERS AND SUN
DAMAGE
Chairs: Dr A. Sheridan and Dr S.W.
Lim
Dr E. TanghettiPDL versus IPL versus fractional for
photodamage
Dr J. GreenCombined laser modalities for
photodamage
Questions
1430-1530SESSION 6: SPEED DATING WITH
TRADE
10 minute trade talks in exhibition
area
1700-1830SESSION 7: INJECTING DUMMY
SESSION
Galderma team to conduct injecting
dummy session with consultants and
teams of registrars (Dr C. Martschin
and local faculty).
17
T H E A U S T R A L A S I A N C O L L E G E O F D E R M AT O L O G I S T S 4 8 T H A N N U A L S C I E N T I F I C M E E T I N G
1045-1200“WHAT’S CAUGHT MY EYE”
– AN UPDATE SESSION
Dr C. Duguid
Non melanoma skin cancers
A/Prof. J.W. Kelly Melanoma
Dr J-A. SeeAcne/rosacea/hidradenitis
suppurativa
Dr L. WarrenImmunobullous conditions/
genodermatoses
Dr J. Wayte
Eczema/urticarial disorders
A/Prof.
Drug reactions
S. Zagarella
18
BREAKFAST SESSIONS
0845-1015CONCURRENT
SESSION 6A: GLOBAL
DERMATOLOGY
SYMPOSIUM
Chair: Dr T. O’Brien
Dr T. O’BrienHistory of the International
Dermatology Outreach
Committee
Dr C. Grills/
India
Dr C. Wong
Dr A. Howard
Out of Africa
Dr G. MarshmanWest Timor – lessons for a
dermatologist
Dr T. O’BrienDermatological
anthropology
Dr M. WhitfeldSkin cancer prevention
and education: First Fijian
Albinism workshop
Dr L. RomaniSystem review of the global
prevalence of scabies and
impetigo
Dr P. Kumarasinghe Quiz - cases
CONCURRENT SESSION 6
BREAKFAST SESSIONS
0730-0830CUTERA AUSTRALIA PTY LTD SPONSORED
BREAKFAST: THE LASER DERMATOLOGY
EXPERIENCE USING PICO, NANO
AND MILLI SECOND TECHNOLOGY IN
CONJUNCTION WITH 532NM AND
1064NM WAVELENGTHS
Speaker: Dr J.B. Greene, MD
Dr Jeremy Green will present two of the most
popular wavelengths in dermatology, 532nm
KTP and 1064nm Nd:YAG for treatment
of tattoos, pigmented lesions and vascular
conditions. Dr Green will introduce Cutera’s
Enlighten dual wavelength laser with the
ability to produce pico second and nano
second pulse durations in a single system.
Dr Green will also present on the variety of
conditions that can be treated with the new
gold standard for vascular lesions, Cutera’s
Excel V.
CONCURRENT SESSION 6
Tuesday 19 May 2015
0730-0830GALDERMA
SPONSORED
BREAKFAST:
FROM LAMP
TO LIGHT:
HOW TO
PERFORM
DAYLIGHT
ACTIVATED
PDT
Chair: Dr L.
Spelman
0845-1015CONCURRENT SESSION
6B: ALL ABOUT ACNE:
ERUPTIONS ON THE ACNE
FRONT – CONTROVERSIES
AND CHALLENGES
Chair: Dr J-A. See
Presentations and panel
discussions covering what’s
new, what’s changed and
what continues to baffle us!
Presenters: Dr J-A. See
A/Prof. K Gebauer
Dr B. De’Ambrosis
Dr M. Tam
Dr I. McCrossin
and more
1330-1345CONTINUING PROFESSIONAL
DEVELOPMENT
Presenter: D
r A. Lewis
Convenor of the ACD
CPD Committee
1345-1445
PLENARY SESSION 3
Prof. A. YanThe year in review: Update on
paediatric dermatology
Prof. A. YanInpatient consultative paediatric
dermatology
1445-1500PRESENTATION OF AWARDS AND
CLOSING REMARKS
A U S T R A L A S I A N S O C I E T Y O F C O S M E T I C D E R M AT O L O G I S T S 2 N D A N N U A L M E E T I N G
Tuesday 19 May 2015
0845–0945SESSION 8: INTRODUCTION TO
SKIN CARE AND SKIN CARE PANEL
Chairs: Dr K. Armour
and Dr A. Rudd
A/Prof. Should we sell skincare in our
S. Zagarella
practices?
Dr N. Wines
Nutraceuticals
Panel discussion Industry Input
Mr R. Parker,
New technology in sunscreens
Rationale
Ms I. Ciavarra, Eye Creams
Obagi Skin Care
Ms T. Vinson,
Mineral Make Up
Synergie
Panel discussion
0945–1030
SESSION 9: FILLERS
Chairs: Dr M. Rich and Dr A. Lim
Dr C. Martschin Skin boosters and Emervel range
Dr T. WalkerPushing the boundaries: Radiesse
injection beyond the face: Hyper
dilution for neck and arm
Questions
1100–1215SESSION 9: FILLERS (CONTINUED)
Panel (international and local
speakers): Fillers with suggested
treatment guidelines
Upper face
Mid face
Lower face
1215-1300SESSION 10: BOTULINUM TOXIN
Chairs: Dr L-M. Yap
and Dr E. Dawes-Higgs
Dr T. WalkerCombination use of filler and
neurotoxin
Dr C. Martschin Hyperhidrosis
Panel
1400-1445SESSION 10: BOTULINUM TOXIN
(CONTINUED)
Chairs: Dr L-M. Yap
and Dr E. Dawes-Higgs
Dr T. Walker
Avoiding neurotoxin complications
Expert panel
Difficult cases
1445-1530SESSION 11: LASERS
Chairs: Dr D. Lim and Dr P. Bekhor
Dr E. TanghettiSuperficial fractional Picosecond with
focus handpiece for rejuvenation
Dr J. Green
Short pulsed lasers
Questions
1600-1700
SESSION 12: DEBATES
First debate: Cryolipolysis is now the
preferred fat reduction modality for
dermatology practices in Australia
Chairs: Dr B. Pruim and Dr D. Lanzer
Affirmative: D
r B. Pruim and A/Prof.
Greg Goodman
Negative: Dr D.Lanzer and Dr M.
Rich
Sum up and adjudication: Dr
E. Tanghetti, with the help of
audience
Second Debate: Are men worth the
trouble?
Chairs: Dr C. McDonald and Dr E.
Yiasemides
Affirmative: D
r B. Welsh and Dr B.
Pruim
Negative: Dr C. McDonald and A/
Prof. P. Foley
Overview of the differences between
treating men and treating women
with procedures, managing their
expectations
Minor but annoying complaints
Chairs: Dr S. Richards and Dr V.
Morgan
PanelSeb Ks, sebaceous hyperplasia, skin
tags, milia, intradermal naevi
Panels on smaller procedures
FWD, shave, snip biopsy, punch
techniques, subcision, curette
Acne scarring
19
The following posters will be displayed at the meeting:
1.
Dr l. Abdel-Malek
Use of adhesive retention tapes to anchor surface
sutures in random pattern flaps: Designs, plans
and options
16. Dr H.M. Cheng
Optical coherence tomography in the presurgical
margin delineation of Mohs surgery in infiltrative
BCC
2.
Dr M. Abikhair
Treatment refractory atopic dermatitis with
ichthyosis vulgaris responding to Omalizumab
17. Dr A. Chia
Safety of TNF-? inhibitors in HIV patients
3.
Dr S. Andrews
Tele-derm national highlights: Eruptive xanthomas
heralding type V hyperlipidaemia
18. Dr Y.Z. Chiang
Biochip immunofluorescence microscopy as a new
diagnostic tool for autoimmune blistering skin
diseases in Australia
4.
Dr S. Andrews
Tele-derm national highlights: Bullae on the
lower legs of a 90-year-old woman - a diagnostic
challenge
19. Dr D. Choi
Another chemotherapy reaction?
Hyperpigmentation due to alkylating agents
revisited
5.
Dr S. Andrews
Tele-derm national: Diagnostic highlights and
management gems
6.
Dr R. Anforth
Factors influencing the development of cutaneous
squamous cell carcinomas in patients on BRAF
inhibitor therapy
20. Dr M. Cicchiello
Radiotherapy-induced eruptive keratoacanthomas
of the face - a case of Ferguson-Smith disease
responsive to acitretin therapy
7.
Miss R. Ang
The autoimmune bullous disease quality of life and
treatment of autoimmune bullous disease quality
of life questionnaires - trends and responsiveness
22. Dr A. Collins
Secukinumab 300mg demonstrates highest
probability of efficacy than other biologics in
psoriasis: indirect comparison
8.
Miss R. Ang
The treatment intensity scoring system and
treatment adversity scoring system - two scoring
systems for treatments used in autoimmune
blistering diseases
23. Dr V. Cox
Review of the proposed pathogenic mechanisms
underlying rosacea and possible clinical
implications of vascular and inflammatory
involvement
9.
Dr S. Arnold
The Oxford University Hospital’s inpatient email
advice line
24. Dr G. Daley
Lipohypertrophy after autologous fat
transplantation for lip enhancement
10. Dr L. Byrom
Undiagnosed severe neonatal ichthyosis: The role
of genetic testing
11. Dr G. Carlos
Bullous annular lichen planus in a patient on
Pembrolizumab
12. Dr P. Chadha
Secukinumab treatment leads to proteomic and
transcriptional changes in psoriatic skin
13. Dr C. Chaptini
Durable dermatology life quality index (DLQI)
improvements in patients on biologics associated
with psoriasis areas and severity index (PASI) score
20
21. Dr P. Clarke
The proportion of the Australian population which
develops skin cancer
25. Dr G. Daley, Ms K. Lee and Ms K. Jadirdar
Glutathione S-transferase P1 Ile105Val
polymorphism: phenotypic characteristics and
melanoma risk
26. Dr B. Daniel
An Australian perspective on skin of colour: results
of a national survey
27. Dr D. Daniels
Protecting the delicate skin of infants
28. Dr C. de Belilovsky
Sunflower oleodistillate: A topical PPAR-? agonist
developed for atopic dermatitis
14. Dr C. Chaptini
Gross hepatomegaly secondary to AA amyloidosis
in RDEB: An under-recognised complication
29. Dr C. de Belilovsky
Tolerance assessment of cosmetic products
dedicated to baby’s skin: Innovative approaches
using stinging test and infant epidermis model
15. Dr H.M. Cheng
Assessment of the optimal interval for digital
dermoscopy monitoring for the evaluation of
pigmented nail lesions
30. Dr C. de Belilovsky
Identification of specific markers for epidermal
maturation in infancy leading to a new generation
of baby skin care
31. Dr C. de Belilovsky
Avocado perseose, a biomimetic active ingredient
for the protection and accompaniment of infants’
skin
45. Dr D. Gaffney
Clear cell renal carcinoma presenting as a skin
papule on the nose: A rare presentation with
variable prognosis
32. Dr C. de Belilovsky
Anti-itching and barrier restoring effects of a Lipidreplenishing Balm on atopic dermatitis models
46. Dr A. Gin
Trichodysplasia spinulosa
33. Dr K. Deen
Porphyria cutanea tarda masquerading as
epidermolysis bullosa acquisita - a report of two
cases
34. Dr L. Demediuk
Multifocal panniculitis due to Mycobacterium
Ulcerans: An unusual presentation of an
increasingly common disease
35. Mr H. Edwards
Advancement in calciphylaxis management: report
of 3 cases
36. Mr L. Escudero Herra
Multi-country, cross-sectional study to determine
patient-specific and general beliefs toward
medication and their treatment adherence to
selected systemic therapies in 6 chronic immunemediated inflammatory diseases (ALIGN)
37. Mr L. Escudero Herra
Safety and efficacy of Adalimumab in patients
with moderate to severe hidradenitis suppurativa:
results from first 12 weeks of PIONEER I, a phase
3, randomized, placebo-controlled trial
38. Mr L. Escudero Herra
Efficacy and safety of Adalimumab in patients
with moderate to severe hidradenitis suppurativa:
results from PIONEER II, a phase 3 randomised
placebo-controlled trial
39. Dr B. Fergie
Perforating paraneoplastic granuloma annulare of
the hands and feet - two cases reported
40. A/Prof. P. Foley
Secukinumab shows efficacy in subjects with and
without previous exposure to biologic psoriasis
therapy: Subanalysis from the phase 3 FIXTURE
study
41. A/Prof. P. Foley
Secukinumab treatment sustains patient-reported
outcome benefits through 1 year
42. A/Prof. P. Foley
Tofacitinib withdrawal and retreatment in
moderate-to-severe chronic plaque psoriasis: A
Phase 3 randomized trial
43. A/Prof. P. Foley
Long-term safety and tolerability of Apremilast in
patients with psoriasis: pooled safety analysis of
the ESTEEM 1 and 2 trialsDr S. Gabizon
Statins reduce the risk of melanoma: Truth or
myth?
44. Dr S. Gabizon
Statins reduce the risk of melanoma: Truth or
myth?
47. A/Prof. G. Goodman
ReCell - an automated kit for the treatment of
hypopigmentation
48. Dr K. Greive
Topical products to relieve and restore sunexposed skin
49. Dr A. Harris
Multiple cutaneous reticulohistiocytomas successfully
treated with topical PUVA combined with
intralesional injections of triamcinolone acetonide
50. Dr A. Harris
The epidermolysis bullosa disease activity and
scarring index (EBDASI) mobile phone application
51. Dr A. Harris
An analysis of the rurality of patients with
epidermolysis bullosa in Australia
52. Dr A. Harris
Combining microneedling and triamcinolone
- a novel way to increase the tolerability of
intralesional corticosteroid delivery in children with
alopecia areata
53. Dr A. Harris
Skin needling as a treatment for acne scarring: An
up to date review of the literature
54. Dr C. Higgins
Psoriasis severity is influenced by nutritional intake:
Results of a dietary and lifestyle questionnaire in
Victorian psoriasis patients
55. Miss L. Illingworth
Risk factors for melanoma in Tasmania: Can
targeted screening be achieved?
56. Dr A. Ingham
Nasal bridge skin necrosis following regular use of
CPAP ventilation pressure mask
57. Miss S. Jain
Characterising severity and responsiveness of a
new outcome measure for epidermolysis bullosa
- the epidermolysis bullosa disease activity and
scarring index
58. Dr H. Jones
Validation of the physician global assessment and
BSA composite tool as an alternative to the PASI
for psoriasis assessments
59. Dr C. Kalai
Cross-reactivity between multiple classes of topical
corticosteroids in a treatment-resistant groin
dermatitis
60. Dr M. Khalesi
Comparison of P53, COX-2, PTCH1 and Ki67
gene expression patterns between basal cell
carcinomas at different anatomical sites and of
different subtypes
21
61. Dr B. Kim
How sunSmart are Australian women?
62. Dr J. Kim
Cyclical inguinal keratoderma: A new clinical
entity?
63. Dr J. Kim
Dystrophic calcinosis cutis in the setting of a
myositis/scleroderma overlap syndrome
64. Dr J. Kim
Cutaneous alternaria infection of the hand in an
immunocompromised patient
65. Dr J. Kim
Facial follicular porokeratosis: Two cases from
Western Australia
66. Dr M. Kim
Squamous cell carcinoma in recessive dystrophic
epidermolysis bullosa has high metastasis potential
due to a permissive tumour microenvironment
67. Dr A. Lalji
Diabetes mellitus and necrobiosis lipodica
68. Dr Q. Le
A single-institution experience of paediatric
melanoma in Victoria, Australia
69. Dr A. Lee
Fractional carbon dioxide laser in recalcitrant
vulval lichen sclerosus
70. Dr P.A. Lee
Cardiac medications in dermatology- a review of
the literature
71. Dr N. Linklater
Case of atypical Sweet’s syndrome
72. Dr N. Linklater
Case report of a full thickness burn following the
use of a Chlorhexidine patch
73. Dr N. Linklater
Case of Toxic epidermal necrolysis following a
dogbite
74. Dr N. Linklater
Melanoma - The Royal Hobart Hospital experience
75. Dr H. Lolatgis
Pigmented purpuric eruption following the lines of
blaschko in a child
76. Dr J. Ma
Tiger, tiger: A dermatomal distribution of AGEP
77. Dr N. Maher
Disseminated mycobacterium chelonae infection
78. Dr C. Maiolo
Complications of Hydroxyurea Therapy:
Dermatology the key to diagnosis
79. Miss Nikki McKevitt
Improvement in nail psoriasis in the open-label
extension of a phase-2 trial of ixekizumab in
patients with moderate-to-severe plaque psoriasis
22
80. Miss N. McKevitt
Effects of ixekizumab treatment on quality of life
during 48 weeks of open-label treatment in a
phase-2 trial in psoriasis
81. Miss N. McKevitt
Impact of ixekizumab on blood neutrophil levels
and the incidence of infections caused by Candida
albicans or Staphylococcus aureus
82. Dr R. McQualter
Three IL-17 ligands contribute to psoriasis:
Blockade of IL-17RA signalling with brodalumab
83. Dr R. McQualter
Improvement of psoriasis in subjects with and
without psoriatic arthritis: subanalysis of a
brodalumab (AMG 827) phase 2 study for
moderate to severe plaque psoriasis (PsO)
84. Dr R. McQualter
Maintenance of clinical response with long-term
brodalumab (AMG 827) therapy for psoriasis:
week 144 results from an open-label extension
study
85. Dr R. Meani
Emergence of chemoresistance in a metastatic
basal cell carcinoma patient after complete
response to hedgehog pathway inhibitor
Vismodegib (GDC-0449)
86. Dr R. Meani
Review of the Victorian Melanoma Service - a
statewide multidisciplinary melanoma referral
centre
87. Dr F. Menz
A retrospective study of psoriasis patients treated
with long contact dithranol in a dermatology day
unit
88. Dr R. Minocha
Systemic and erythrodermic reaction following
repeated exposure to bites from the common bed
bug, Cimex lectularius
89. Dr R. Minocha
Interstitial granulomatous dermatitis presenting
with scleroderma-like changes associated with
dystrophic calcification and a review of the
literature
90. Dr R. Minocha
Necrobiotic xanthogranuloma: A report of two
unique cases
91. Dr R. Minocha
The progressive clinical course of Cimicosis; the
dermatological affects from the common bed bug,
Cimex lectularius
92. Dr E. Mooney
Chromonychia: A brief review
93. Dr E. Mooney
Kaposi’s sarcoma
94. Dr D. Norris
Treatment of granuloma faciale with intralesional
Kenacort-A 10 and 5-Fluorouracil combination
therapy
95. Dr D. Norris
Reduced levels of self-reported psychological
distress associated with multidisciplinary
melanoma clinic attendance
96. Dr D. Norris
Dermatology life quality index in the Australian
psoriasis population
97. Dr A. O’Connor
Stewart-Bluefarb syndrome secondary to
arteriovenous malformations and acquired nontraumatic arteriovenous fistula: Report of five cases
and a review of literature
98. Dr N. Ong
My patient has loss of MSH2 and 6 in their
sebaceous adenoma; do they have Muir Torre
syndrome?
99. Dr N. Ong
Molecular profiles of reticular and globular naevus
patterns: A pilot study
100. Dr N. Ong
A clinical audit of high-cost approved drugs in
dermatology: 2003 - 2013
101. Dr G. Parham
Understanding longitudinal melanonychia
102. Dr G.Parham
Linear erythematous cutaneous adverse reaction
during intravenous Iloprost administration
103. Dr P. Peters
Adult Blaschkitis: An unusual unilateral
presentation
104. Dr L. Pitney
Intermittent combined low dose UVA1/
narrow band UVB therapy for cutaneous T-Cell
lymphoma/Sezary syndrome: Report of a case and
discussion of its implications
105. Dr M. Pitney
Scleredema of Buschke: A report of associated
acute bowel obstruction and review of systemic
complications
106. Dr F. Poon
Severe erosive lichen planus of the penis treated
effectively with oral acitreitin
107. Dr F. Poon
Return of the great masquerader: A review of the
resurgence of Syphilis in Australia through clinical
vignettes
108. Dr F. Poon
The impact of an outpatients’ online handover
tool: Timely follow-up and safe patient care in the
Dermatology Department at The Royal Melbourne
Hospital
109. Dr H. Rajgopal Bala
Two cases of acute amoxycillin induced follicular
pustulosis
110. Dr J. Raymond
Congenital Becker’s naevus - a case report and
literature reviewDr J. Read
Familial melanoma and links with other cancers
111. Dr J. Read
Familial melanoma and links with other cancers
112. Dr S. Richter
Apremilast, an oral phosphodiesterase 4 inhibitor,
in patients with moderate to severe psoriasis: 52week results of the ESTEEM 2 trial
113. Dr S. Richter
Apremilast, an oral phosphodiesterase 4 inhibitor,
in patients with nail, scalp, and palmoplantar
psoriasis: 52-week ESTEEM 2 study results
114. Ms L. Romani
Scabies and impetigo prevalence and risk factors
in Fiji: A national survey
115. Dr A. Ross
Cognitive function in patients with psoriasis while
on biologic therapies: Pilot study
116. Dr C. Rowe
Psychological impact of chronic childhood skin
disease on caregivers and families: A review
117. Dr C. Rowe
Immune cell infiltrate subtypes inform on
melanoma survival in stage Ib and II melanomas
118. Dr A. Sahebian
A review on uncommon malignancies associated
with dermatomyositis
119. Dr A. Sahebian
Prevalence of actinic keratosis and the risk factors
for skin cancer in lung transplant recipients in
Queensland, Australia
120. Dr R. Saunderson
Palisading neutrophilic granulomatous dermatitis
secondary to a novel anti-diabetic medication,
dapagliflozin
121. Dr R. Saunderson
Antibiotic therapy for Staphylococcus aureus
colonised vascular catheter tips and the occurrence
of bacteraemia - implications for hospital policy
122. Mr A. Shahnam
Sun protection practices of undergraduate
university students
123. Dr S. Shen
The unique clinical behaviour of desmoplastic
melanoma
124. A/Prof. S. Shumack
Secukinumab shows efficacy in subjects with and
without previous exposure to biologic psoriasis
therapy: Subanalysis from the phase 3 FIXTURE
study
125. Prof. R. Sinclair
Psoriasis patients with PASI90 response achieve
greater health-related quality of life improvements
than those with PASI75 response
126. Dr S. Sinnya
Use of mobile app for patient information in solid
organ transplantation - minimising gaps in patient
education
23
127. Dr S. Sinnya
Emergence of squamous cell carcinomas post
Nilotinib therapy for chronic myelogenous
leukemia - a rare adverse effect of a second
generation tyrosine kinase inhibitor
128. Dr E. Smith
Cutaneous melioidosis
145. Dr J-M. Tan
Histopathological features after topical black salve
application
129. Dr S. Smith
Assessment of the attitude of dermatologists to the
use of topical corticosteroids in paediatric atopic
dermatitis
146. Dr J-M. Tan
Eosinophilic folliculitis in a patient receiving
chemotherapy for chronic lymphocytic leukaemia case report and review of the literature
130. Dr S. Smith
Assessment of attitudes towards sun-protective
behaviour in Australia: A cross-sectional study
147. Dr J-M. Tan
Localised neutrophilic eccrine hidradenitis
secondary to 5-Fluorouracil infusion for mixed
adenoneuroendocrine tumour
131. Dr S. Smithson
Trends In thickness and survival of primary in situ
and invasive cutaneous melanoma In Victoria,
Australia
132. Dr S. Smithson
Prognosis of melanoma of unknown primary
133. Dr P. Sobarun
Porphyria cutanea tarda in a patient on
haemodialysis and iron deficiency
134. Dr S. Sokolovska
Outcomes of pemphigus treatments at the
Royal Melbourne Hospital over 5 years on
immunosuppressive therapies used over this time:
a retrospective analysis
135. Dr S. Sokolovska
Treatment of Behcets disease with subcutaneous
testosterone: A case report
136. Dr L. Spelman
Secukinumab treatment provides fast relief from
patient-reported psoriasis burden
137. Dr L. Spelman
Secukinumab shows efficacy regardless of baseline
disease severity in subjects with moderate-tosevere plaque psoriasis: A pooled analysis from
four phase 3 studies
138. Dr S. Strathie Page
Mycophenolic acid: Applications in dermatology
139. Dr S. Strathie Page
Ulcerated rapidly involuting congenital
hemangiomas: A case series
140. Dr S. Strathie Page
Acrodermatitis dysmetabolica
141. Dr S. Strathie Page
Wiskott-Aldrich syndrome in an Australian
population
142. Dr A. Tan
Non-bullous lichen planus pemphigoides likely
induced by venlafaxine
143. Dr A. Tan
A typical presentation of hypomelanosis of ito - a
rare pigmentary chromosomal mosaicism
24
144. Dr A. Tan
Allergic contact dermatitis and systemic symptoms
from wearing the new navy blue South Australian
police uniform
148. Dr J-M. Tan
A case of carbimazole-induced lichenoid drug
eruption
149. Dr W.P. Tan
The perialar cresenteric advancement flap - a
versatile flap for repair of nasal dorsum and upper
cutaneous lip defects
150. Dr C. Thomas
A case of mistaken identity: unilateral erythema
elevatum diutinum associated with IgA
paraproteinaemia
151. Dr C. Thomas
“The physician who knows syphilis knows
medicine”: Secondary syphilis masquerading as
pityriasis rosea
152. Dr C. Thomas
MEK-Inhibitor induced compound skin toxicity with
oedema in metastatic malignant melanoma: A
case series
153. Dr B. Thompson
Skin infection secondary to Purpureocillium
lilacinum associated with a spider bite in an
immunocompetent patient - a rare case report
154. Dr A. Thornton
Background exercise and creatine kinase levels in
acne patients commencing isotretinoin
155. Dr S. Tizi
Oculocutaneous Tyrosinaemia - a case report of a
late diagnosis at age 17
156. Dr N. Torkamani
Cells expressing epidermal stem cell markers
are exclusively localised at the distal end of the
arrector pili muscle in non-glabrous skin
157. Dr E. Trowbridge
Congenital cutaneous candidiasis: A rare neonatal
disease
158. Dr L. von Schuckmann
Vitamin D receptor polymorphisms and
keratinocyte skin cancers: A cohort study and
meta-analysis
159. Dr L. von Schuckmann
Body hair density and risk of keratinocyte skin
cancer in Australian adults
160. Dr A. Wallett
Radiation therapy induced neuro-Sweet’s disease
in a patient with oral squamous cell carcinoma
161. Dr G. Whiting
General practice registrars’ clinical experience of
dermatology during training: A cross-sectional
analysis from the registrar clinical encounters in
training study
162. Miss A. Wijayanti
Validity, reliability, responsiveness and minimal
clinically important difference of the bullous
pemphigoid disease area index (BPDAI)
163. Dr G. Winkler
The use of biologic agents for hidradenitis
suppurativa by Australian dermatologists
164. Dr C. Wong
Teledermatology: A one year experience from a
Victorian tertiary hospital.
165. Dr A. Wylie
Secukinumab shows sustained response in subjects
with moderate-to-severe plaque psoriasis: A
subanalysis of the ERASURE phase 3 study
166. Dr C. Xie
Chronic granulomatous disease and lupus
erythematosus
167. Dr C. Xie
Scalp melanoma has a distinct clinical
presentation and aggressive histologic features
168. Dr B. Yau
Cutaneous SCC with dermal lymphatic spread:
When surgery is not enough
169. Dr C. Zhao
Telogen effluvium and Beau’s lines induced by
azathioprine: A case report
170. Dr C. Zhao
Severe ingenol mebutate skin reaction while on
methotrexate: A case series and proposal of
pathogenesis
171. Dr C. Zhao
Chlorophyll-induced pseudoporphyria with
ongoing photosensitivity after cessation - a case
series of 5 patients
172. Dr C. Zhao
Assessing skin diseases in patients with pigmented
skin - A grey area
173. Dr C. Zhao
Recording of dermatology consults in discharge
summaries: An analysis of 218 consults
174. Dr C. Zhao
A prospective comparison study of four outcome
measures for atopic dermatitis
25
The following events have been organised for delegates and accompanying persons.
All prices quoted include GST.
Please indicate your intention to attend the social functions on the registration form.
Saturday 16 May 2015
Monday 18 May 2015
1900-2400TASTE SA: CONFERENCE DINNER,
PANORAMA BALLROOM, ACC
Come and join us at the new-look
conference dinner. Less formal
than in previous years, but still
giving everyone an opportunity to
enjoy good conversation, music
and great food! A variety of tastes
and flavours from around South
Australia will be on offer, presented
in a fun, novel way. Set in the new
Panorama Ballroom of the recentlyextended Adelaide Convention
Centre, “Taste SA” will offer beautiful
views of Adelaide’s latest additions
to the map, aligned along the River
Torrens. Enjoy what the state has to
offer, along with cool jazz and the
company of friends and colleagues.
Music by the well-known Adelaide
jazz band, Black Fedora, http://
blackfedora.info.
Cost: For all delegates who are fully
registered, the cost is included
in the ASM registration fee.
Please note dinner cost
included in the registration fee
is not transferable.
For partners of above and
others, the fee is:
$165.00
1800-2000MEN’S AND LADIES TENNIS
TOURNAMENT
Venue: N
ext Generation Health and
Racquet Club
War Memorial Drive
NORTH ADELAIDE
T 08 8110 7777
Cost: $30.00 per person
Sunday 17 May 2015
1830-1930GRADUATION ORATION AND
CONFERRING OF DIPLOMAS AND
AWARDS, HALL L, ACC
John Reid Orator: Dr Peter
Goldsworthy, AM
Australian writer
and medical
practitioner
Light refreshments will be available
for graduands and their guests
following the ceremony.
26
Tuesday 19 May 2015
0930-1130PRIVATE TOUR OF ADELAIDE
CENTRAL MARKET AND
BREAKFAST
Since 1869, the Central Market has
been the jewel in the crown of South
Australian Tourism experiences, a
haven of premium food and wine
products, and second home to
chefs and food lovers. The tour is
a sensory and interactive gourmet
walking tour with a local food
expert. Participants enjoy a range
of delicious samples that represent
the multicultural community of South
Australia and the clean and green
produce harvested from our farms
and oceans.
Cost: $80.00 per person
1230-GOLF
Venue: R
oyal Adelaide Golf Club
328 Tapleys Hill Road
SEATON
T 08 8356 5511
Tee off:1300
Cost: $120.00 per person
(includes light lunch and
drinks afterwards)
(maximum 16 people)
The College has appointed as accommodation brokers for College’s meeting:
Info Salons Australia Pty Ltd
PO Box K1385
HAYMARKET NSW 1240
T +61 2 9280 1295
F +61 2 9211 7470
Edermatology@infosalons.com.au
College has selected a range of hotels and apartments in Adelaide. Info Salons has block booked
accommodation at all these venues. This service is free for delegates.
Full descriptions of the hotels, together with details of accommodation types and rates can be seen on the
College website, http://bit.ly/ACD-accom2015.
Bookings can be made through the College website or on the accompanying accommodation form.
The Australasian College of Dermatologists kindly acknowledges
the generous support of the following sponsors in assisting with the
Annual Scientific Meeting:
Platinum Sponsor
Gold Sponsors
Others
27
THE
OFDERMATOLOGISTS
DERMATOLOGISTS
THEAUSTRALASIAN
AUSTRALASIAN COLLEGE
COLLEGE OF
48TH
ANNUAL
SCIENTIFIC
MEETING
48th
ANNUAL
SCIENTIFIC
MEETING
2015
Please note that Annual Scientific Meeting and the
Trade Exhibition are managed on behalf of the College
by ACD Educational Enterprises Pty Ltd as Trustee for
the ACD Educational Enterprises Unit Trust.
ACD Educational Enterprises Pty Ltd as Trustee for
the ACD Educational Enterprises Unit Trust
PO Box 3785, RHODES NSW 2138, Australia
T +61 2 8765 0242
or 1300 361 821 (within Australia only)
F +61 2 9736 2194
E admin@dermcoll.edu.au
W http://www.dermcoll.edu.au